13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13D/A Filed 2026-06-03 Event 2026-05-29 SEC 0001674752-26-000002 →

Pittman Scott M. Nuo Therapeutics, Inc. AURX

Stake: 11.60% Shares: 5,627,500 CUSIP: 67059V209 Class: Common Stock, $0.0001 par value per share

Item 4 — Purpose of Transaction

Item 4 of this Schedule 13D is hereby amended as follows: On January 23, 2026, the closing (the "Initial Closing") occurred of a Loan and Security Agreement dated January 21, 2026 (the "Initial Loan Agreement") among the Company and certain lenders (including the Reporting Person). Upon the Initial Closing, the Reporting Person loaned $200,000 to the Company and, pursuant to the Initial Loan Agreement, committed to loaning $410,000 in a second funding, if requested by the Company, to be held on September 30, 2026 (a "Second Closing"). On May 29, 2026, the closing (the "Interim Closing") occurred of an Amended and Restated Loan and Security Agreement dated May 29, 2026 (the "Interim Loan Agreement") among the Company and certain lenders (including the Reporting Person). The Interim Loan Agreement amended and restated the Initial Loan Agreement. Upon the Interim Closing, the Reporting Person loaned $100,000 to the Company and, as amended pursuant to the Interim Loan Agreement, committed to loaning $100,000 in the Second Closing. At the Initial Closing, the Company issued a Secured Promissory Note (the "Initial Note") to each of the lenders (including the Reporting Person), at the Interim Closing, the Company issued a Secured Promissory Note (the "Interim Note") to each of the lenders (including the Reporting Person), and upon a Second Closing, if any, the Company will issue an additional Secured Promissory Note (a "Second Note") to each of the lenders (including the Reporting Person). The terms of the Initial Notes initially provided that they would bear interest at an annual rate of 10%; however, as amended pursuant to the Interim Loan Agreement, the interest rate of the Initial Notes increased to an annual rate of 12% as a result of the Interim Closing. The Interim Notes bear interest at an annual rate of 12%. Upon a Second Closing, the Second Notes will bear interest at an annual rate of 12%. The maturity date of the Initial Notes, Interim Notes, and any Second Notes is December 31, 2028 (the "Maturity Date"). Interest on the Initial Notes, Interim Notes, and, if any, the Second Notes (together, the "Notes") will be payable in Interest Warrants as described below, and not in cash. Interest on the Notes will be payable and issued at the Maturity Date (or earlier upon certain prepayments as described below). Interest on the Notes will accrue on a quarterly calendar basis with partial quarters being treated as full quarters for accrual purposes. The Notes are interest only through December 31, 2026. The principal on the Notes is repayable in cash in equal quarterly installments on the last business day of each calendar quarter commencing March 31, 2027 and continuing to the Maturity Date. The Company may, at its option on the last business day of a calendar quarter commencing December 31, 2026, voluntarily prepay the Notes in their entirety by paying the then outstanding principal balance and all accrued interest on the Notes, subject to a prepayment fee equal to 1.5% of the then outstanding principal balance if the Notes are prepaid on or after December 31, 2026 but before December 31, 2027, with no prepayment fee applicable to such prepayments on or after December 31, 2027. The prepayment fee, if any, is payable in Prepayment Restated Warrants as described below, and not in cash, that vest in the event of a voluntary prepayment. In addition, prepayment of the Notes is mandated in the event of (A) an equity financing by the Company of at least $5 million, (B) certain changes in control of the Company as defined in the Interim Loan Agreement, or (C) a default by the Company. In the event of such an equity financing or change in control, the Company has agreed to repay the Notes in their entirety by paying the then outstanding principal balance and all accrued interest on the Notes, subject to a prepayment fee equal to 2.75% of the then outstanding principal balance if such event occurs before December 31, 2026 and 1.5% of the then outstanding principal balance if such event occurs on or after December 31, 2026 but before December 31, 2027, with no prepayment fee applicable if such event occurs on or after December 31, 2027. In the event of a default, the Company has agreed to repay the Notes in their entirety by paying the then outstanding principal balance and all accrued interest on the Notes, subject to a prepayment fee equal to 2.75% of the then outstanding principal balance. The prepayment fee, if any, is payable in Prepayment Restated Warrants as described below, and not in cash, that will vest in the event of a mandatory prepayment. The Notes are secured by a lien upon and security interest in all of the Company's assets, including intellectual property. The Interim Loan Agreement contains customary representations, warranties, and covenants. The foregoing description of each of the Initial Loan Agreement and the Interim Loan Agreement does not purport to be complete and is qualified in its entirety by

Cross-References

Insider Activity (last 365d)
8 transactions
6 buys · 2 sales · 0 awards/exercises
Issuer Cluster
4 13D/G filings on this issuer
3 other filings besides this one
Filer Track Record
3 filings by this filer
2 other filings in the data moat
Short Interest · settle 2026-07-15
DTC 1.00
75 shares short · 0.0% vs prior

Post-Filing Returns · since 2026-05-29 on AURX

+1 day
+3.0%
+5 days
+7.1%
+30 days
+2.0%
+60 days
-9.1%
+90 days
+180 days

Anchor price 0.99 on closest trading day on/after 2026-05-29. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Form 4 Insider Transactions · last 365d

DateInsiderRoleTypeSharesPriceValue
2026-05-29 Pittman Scott M. director, 10%+ owner Award 17,450 $1.50 $26K
2026-05-29 Pittman Scott M. director, 10%+ owner Disposition 36,750 $1.50 $55K
2026-05-29 Pittman Scott M. director, 10%+ owner Disposition 7,516 $1.50 $11K
2026-05-29 Pittman Scott M. director, 10%+ owner Award 17,500 $1.50 $26K
2026-05-29 Pittman Scott M. director, 10%+ owner Award 7,333 $1.50 $11K
2026-01-23 Pittman Scott M. director, 10%+ owner Award 30,050 $1.50 $45K
2026-01-23 Pittman Scott M. director, 10%+ owner Award 36,750 $1.50 $55K
2026-01-23 Pittman Scott M. director, 10%+ owner Award 7,516 $1.50 $11K

Other 13D/G Filings on Nuo Therapeutics, Inc.

FiledFormFilerStakeShares
2026-01-26 SCHEDULE Pittman Scott M. 11.60% 5,610,050 view →
2022-07-05 SC Pittman Scott M. view →
2022-07-05 SC SHEEDY CHARLES E view →

Other Filings by Pittman Scott M.

FiledFormIssuerStakeShares
2026-01-26 SCHEDULE Nuo Therapeutics, Inc. AURX 11.60% 5,610,050 view →
2022-07-05 SC Nuo Therapeutics, Inc. AURX view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →